The QuickScreen™ Barbiturates Test is a rapid, qualitative immunoassay for the detection of Barbiturates in urine. The cutoff concentration for this test is 300 ngdomly This assay is intended for professional use.

QuickScreen Multi Drug Screening Test is a rapid, qualitative immunoassay for the detection of the target drugs/drug metabolites in urine. The cut-off concentrations of this test are as follows: Amphetamine; 1000 ng/ml Barbiturates: 300 nq/ml Benzodiazepines: 200 na/ml Cocaine; 300 ng/ml Methadone 300 nq/ml Methamphetamine; 1000 ng/ml Opiates: 2000 ng/ml. Phencyclidine (PCP) 25 ng/ml THC: 50 nq/ml This assay is intended to assist in the prevention of drug abuse

The QuickScreen Barbiturates Test is a qualitative in-vitro diagnostic screen that provides a preliminary result for the detection/presence of Barbiturates in urine. Tests for barbiturates cannot distinguish between abused drugs and certain prescribed medications. The cut-off concentration will be 300 ng/ml (secobarbital). It is intended for professional use only.

An invitro diagnostic test for the qualitative detection of amphetamine, cocaine, methamphetamine, opiates, PCP, Barbiturates, benzodiazepines, methadone and THC in urine. Tests for prescription drugs cannot distinguish between abused drugs and certain prescribed medications. Measurements obtained by this device are used in the diagnosis and treatment of drug abuse. It is intended for professional use only.

Device Description

Immunoassay for the qualitative detection of Barbiturates in urine

Immunoassay for the qualitative detection, Amphetamine, THC, Cocaine, PCP, Barbiturates, Benzodiazepines, Methadone, Opiates and Methamphetamine in urine

AI/ML Overview

The Phamatech QuickScreen™ Barbiturates Test (Models 9019, 9018) and the QuickScreen Multi Drug Screening Test (Models 9317T and 9187Z) are qualitative immunoassays for the detection of drugs/drug metabolites in urine. This summary addresses the performance of both devices as described in the provided 510(k) summaries.

Acceptance Criteria and Device Performance

The acceptance criteria for the QuickScreen™ Barbiturates Test and the QuickScreen Multi Drug Screening Test are implied through their claims of substantial equivalence to predicate devices and established laboratory methodologies. The performance is assessed by correlation studies against these benchmarks.

For QuickScreen™ Barbiturates Test:

Acceptance Criteria (Implied)	Reported Device Performance
Substantial equivalence to commercially available predicate devices (e.g., ABMC RapidOne BZD test)	97.9% correlation when compared to the predicate devices.

For QuickScreen Multi Drug Screening Test:

Acceptance Criteria (Implied)	Reported Device Performance
Substantial equivalence to Behring EMIT II and GC/MS methodology	>98% correlation when compared to Behring EMIT II and GC/MS.
Excellent overall accuracy in the hands of professional users	>97% overall accuracy.

Study Details

The information provided covers both the QuickScreen™ Barbiturates Test and the QuickScreen Multi Drug Screening Test. The studies performed were clinical sample correlation studies and blind labeled spiked studies.

1. Sample Size and Data Provenance:

QuickScreen™ Barbiturates Test: The number of clinical samples used for the correlation study is not specified, only that "clinical specimens" were used. The country of origin for the data is not explicitly stated, but the manufacturer is based in San Diego, California, USA. The studies appear to be retrospective as they involve evaluating existing samples or spiked samples.
QuickScreen Multi Drug Screening Test: The number of clinical samples, urine samples, and the specific composition of the blinded spiked samples is not specified. Clinical studies were performed at two independent laboratories. The country of origin for the data is not explicitly stated, but the manufacturer is based in San Diego, California, USA. The studies appear to be retrospective as they involve evaluating existing samples or spiked samples.

2. Number of Experts and Qualifications:

The 510(k) summaries do not specify the number of experts or their qualifications for establishing ground truth for the test sets. The tests are intended for "professional use," and the Multi Drug Screening Test exhibited "excellent overall accuracy (>97%) in the hands of professional users," implying that professionals (likely lab technicians or clinicians) performed the assessments for the device.

3. Adjudication Method:

The 510(k) summaries do not describe an adjudication method. The clinical sample correlation studies compare the device's results directly against predicate devices (Barbiturates Test) or Behring EMIT II and GC/MS methodology (Multi Drug Screening Test). The "blind labeled spiked study" implies that the labels of the spiked samples were not known to the testers.

4. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

No MRMC comparative effectiveness study was explicitly mentioned. The studies focus on the device's performance against reference methods rather than comparing human reader performance with and without AI assistance. The devices are point-of-care immunoassay tests, not AI-assisted diagnostic tools requiring human interpretation.

5. Standalone Performance (Algorithm Only):

Yes, performance was evaluated in a standalone manner. These are immunoassay devices that provide a qualitative result directly, without requiring human interpretation other than observing a visual color change. The reported correlations and accuracy reflect the device's direct output.

6. Type of Ground Truth Used:

QuickScreen™ Barbiturates Test: The ground truth for the clinical sample correlation study was established by predicate devices (e.g., ABMC RapidOne BZD test). For the blind labeled spiked study, the ground truth was based on the known concentrations of barbiturates in the spiked samples.
QuickScreen Multi Drug Screening Test: The ground truth for the clinical sample correlation study was established by Behring EMIT II and Gas Chromatography/Mass Spectrometry (GC/MS) methodology. For the blind labeled spiked study, the ground truth was based on the known concentrations of the target drugs/metabolites in the spiked samples. GC/MS is widely considered a gold standard for drug confirmation. Expert opinion is also subtly implied through the requirement for professional use and clinical consideration.

7. Sample Size for Training Set:

The 510(k) summaries do not mention a specific training set or its sample size. These devices are immunoassay tests, not machine learning algorithms that typically require a distinct training set. The development and optimization of such tests usually involve laboratory experiments rather than data-driven training as understood in AI/ML contexts.

8. How Ground Truth for Training Set Was Established:

As there's no mention of a traditional "training set" in the context of an AI/ML algorithm, this question is not directly applicable. The performance characteristics were evaluated through the clinical sample correlation and blind labeled spiked studies, which served to validate the device's accuracy against established methods and known concentrations.

Summary

{0}------------------------------------------------

K070098

510 (k) SUMMARY AS REQUIRED BY SECTION 807.92(C)

ldentification: QuickScreen™ Barbiturates Test: Models 9019, 9018

DEC 07 2007

Description: Immunoassay for the qualitative detection of Barbiturates in urine

Name Of Manufacturer:

Phamatech 10151 Barnes Canyon Road San Diego, California 92121, USA

Intended Use: The QuickScreen™ Barbiturates Test is a rapid, qualitative immunoassay for the detection of Barbiturates in urine. The cutoff concentration for this test is 300 ngdomly This assay is intended for professional use.

Technology: The QuickScreen™ Barbiturates Test, like many commercially available barbiturate screening test kits, qualitatively measures the presence of Barbiturates by visual color sandwich one step immunoassay technology. Examples of such predicated evices include the ABMC RapidOne BZD test (Kinderhook, NY). These devices rely on the hoss immunochemical sandwich assay principle of recognition of specific of specific antibody / target analyte / antibody / complexes.

The product performance characteristics of the QuickScreen™ Barbiturates Performance: Test were evaluated in a clinical sample correlation study and a blind labeled spiked study. The results of these studies demonstrate the QuickScreen™ Barbiturates Test to be substantially equivalent to the reported performance characteristics of other commercially available tests for the qualitative detection of Barbiturates in urine. Laboratory studies, using clinical specimens, produced a 97.9% correlation when compared to the prodicated devices.

For the reasons mentioned above, it may be concluded that the Conclusion: Phamatech QuickScreen™ Barbiturates Test is substantially equivalent to a variety of detection tests currently in commercial distribution and is safe in the hands of the professional user.

{1}------------------------------------------------

510 (k) SUMMARY AS REQUIRED BY SECTION 807.92(C)

Identification: QuickScreen Multi Drug Screening Test: Model 9317T and 9187Z

Description: Immunoassay for the qualitative detection, Amphetamine, THC, Cocaine, PCP, Barbiturates, Benzodiazepines, Methadone, Opiates and Methamphetamine in urine

Name Of Manufacturer:

Phamatech Inc. 10151 Barnes Canyon Road San Diego, California 92121, USA

Intended Use: QuickScreen Multi Drug Screening Test is a rapid, qualitative immunoassay for the detection of the target drugs/drug metabolites in urine. The cut-off concentrations of this test are as follows:

Amphetamine; 1000 ng/ml Barbiturates: 300 nq/ml Benzodiazepines: 200 na/ml Cocaine; 300 ng/ml Methadone 300 nq/ml Methamphetamine; 1000 ng/ml Opiates: 2000 ng/ml. Phencyclidine (PCP) 25 ng/ml THC: 50 nq/ml

This assay is intended to assist in the prevention of drug abuse

The QuickScreen Multi Drug Screening Test, like many commercially available Technology: drug screening test kits, qualitatively measures the presence of target drugs or their metabolites by visual color sandwich one step immunoassay technology. Examples of such predicate devices include the Phamatech QuickScreen At Home Drug Test and the Phamatech QuickScreen Multi Drug Screening Test. All of the above devices rely on the basic immunochemical sandwich assay principle of recognition of specific antibody / target drug / antibody / complexes.

Performance: The product performance characteristics of the QuickScreen Multi Drug Screening Test were evaluated in a clinical sample correlation study and a blind labeled spiked study. The results of these studies demonstrate the Phamatech QuickScreen Multi Drug Screening Test to be substantially equivalent to the reported performance characteristics of other commercially available tests for the qualitative detection of the stated target drugs in urine. Correlation studies, using clinical specimens, produced a >98% correlation when compared to the Behring EMIT II (Cupertino, CA 95014) and GC/MS methodology. Clinical studies, performed at two independent laboratories, were also performed. In them the Phamatech QuickScreen™ exhibited excellent overall accuracy (>97%) in the hands of professional users.

Conclusion: For the reasons mentioned above, it may be concluded that the Phamatech QuickScreen Multi Drug Screening Test is substantially equivalent to a variety of detection tests currently in commercial distribution and is safe

{2}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with its wings spread, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle. The logo is black and white.

Public Health Service

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

DEC 0 7 2007

Phamatech、Inc. c/o Mr. Carl Mongiovi Vice President 10151 Barnes Canyon Road San Diego, CA 92121

Re: K070098

Trade/Device Name: Phamatech QuickScreen™ Barbiturates Test Models 9019, 9018, Phamatech Quick Screen™ Pro Multi Drug Screening Test Model 9317T and 9187Z

Regulation Number: 21 CFR 862.3150 Regulation Name: Barbiturate test system. Regulatory Class: Class II Product Code: DIS Dated: October 30, 2007 Received: November 1, 2007

Dear Mr. Mongiovi:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

{3}------------------------------------------------

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely vours,

Jean M. Cooper, M.S., D.v.M.

Yéan M. Cooper, M.S., D.V.M. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

INDICATIONS FOR USE

Applicant: Phamatech

510 (k) Number (if known): _ K_070098

Device Name: Phamatech QuickScreen™ Barbiturates Test Models 9019 , 9018

Indications for Use:

This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are observed.

Prescription Use: × AND/OR (Part 21 CFR 801 Subpart D

Over the Counter Use: (21 CFR 807 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE -- CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of the CDRH Office of In Vitro Diagnostic Devices (OIVD)

Sean Cooper
Division Sign-Off

Page 1 of 1

Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K070098

{5}------------------------------------------------

INDICATIONS FOR USE

Applicant: Phamatech

510 (k) Number (if known): K 070098 .

Device Name: Phamatech QuickScreen™ Pro Multi Drug Screening Test Model 9317T

Indications for Use:

Amphetamine	1000 ng/ml
Cocaine	300 ng/ml
Methamphetamine	1000 ng/ml
Opiates	2000 ng/ml
PCP	25 ng/ml
Barbiturates (Secobarbital)	300 ng/ml
Benzodiazepines	200 ng/ml
Methadone	300 ng/ml
THC	50 ng/ml

Prescription Use: X (Part 21 CFR 801 Subpart D AND/OR Over the Counter Use: (21 CFR 807 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of the CDRH Office of In Vitro Diagnostic Devices (OIVD)

Olan Cooper
Division Sign-Off

Page 1 of 1

{6}------------------------------------------------

INDICATIONS FOR USE

Applicant: Phamatech

510 (k) Number (if known): K 070098

Device Name: Phamatech QuickScreen™ Pro Drug Cup Model 9187Z

Indications for Use:

Amphetamine	1000 ng/ml
Cocaine	300 ng/ml
Methamphetamine	1000 ng/ml
Opiates	2000 ng/ml
PCP	25 ng/ml
Barbiturates (Secobarbital)	300 ng/ml
Benzodiazepines	200 ng/ml
Methadone	300 ng/ml
THC	50 ng/ml

Prescription Use: X (Part 21 CFR 801 Subpart D

Over the Counter Use: AND/OR (21 CFR 807 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of the CDRH Office of In Vitro Diagnostic Devices (OIVD)

Alan Cooper
Division Sign-Off

Page 1 of 1

510K K070098

Regulation Number and Section

§ 862.3150 Barbiturate test system.

(a)
Identification. A barbiturate test system is a device intended to measure barbiturates, a class of hypnotic and sedative drugs, in serum, urine, and gastric contents. Measurements obtained by this device are used in the diagnosis and treatment of barbiturate use or overdose and in monitoring levels of barbiturate to ensure appropriate therapy.(b)
Classification. Class II (special controls). A barbiturate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).